Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. Among authors: or r. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
Mevorach D, Zuckerman T, Reiner I, Shimoni A, Samuel S, Nagler A, Rowe JM, Or R. Mevorach D, et al. Among authors: or r. Biol Blood Marrow Transplant. 2014 Jan;20(1):58-65. doi: 10.1016/j.bbmt.2013.10.010. Epub 2013 Oct 15. Biol Blood Marrow Transplant. 2014. PMID: 24140121 Free article. Clinical Trial.
Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Eder S, Labopin M, Arcese W, Or R, Majolino I, Bacigalupo A, de Rosa G, Volin L, Beelen D, Veelken H, Schaap NP, Kuball J, Cornelissen J, Nagler A, Mohty M; Acute Leukemia Working Party. Eder S, et al. Among authors: or r. Eur J Haematol. 2016 Jan;96(1):90-7. doi: 10.1111/ejh.12553. Epub 2015 Apr 21. Eur J Haematol. 2016. PMID: 25807864
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D, Veelken H, Bermudez A, Or R, Lioure B, Beelen D, Fegueux N, Hamladji RM, Nagler A, Mohty M. Kharfan-Dabaja MA, et al. Among authors: or r. Leuk Res. 2015 Sep;39(9):933-7. doi: 10.1016/j.leukres.2015.04.009. Epub 2015 Apr 24. Leuk Res. 2015. PMID: 26003666
Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Eder S, Beohou E, Labopin M, Sanz J, Finke J, Arcese W, Or R, Bonifazi F, Aljurf M, Socié G, Passweg J, Giebel S, Mohty M, Nagler A. Eder S, et al. Among authors: or r. Am J Hematol. 2017 Jan;92(1):18-22. doi: 10.1002/ajh.24567. Epub 2016 Nov 18. Am J Hematol. 2017. PMID: 27673280 Free article. Clinical Trial.
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, Or R, Finke J, Cortelezzi A, Beelen D, Passweg J, Socié G, Gurman G, Aljurf M, Stelljes M, Giebel S, Mohty M, Nagler A. Eder S, et al. Among authors: or r. Am J Hematol. 2017 Oct;92(10):997-1003. doi: 10.1002/ajh.24823. Epub 2017 Jul 19. Am J Hematol. 2017. PMID: 28614903 Free article.
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.
Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socié G, Lioure B, Bermudez A, Lopez-Corral L, Or R, Arcese W, Fegueux N, Nagler A, Mohty M. Kharfan-Dabaja MA, et al. Among authors: or r. Bone Marrow Transplant. 2014 Sep;49(9):1170-5. doi: 10.1038/bmt.2014.133. Epub 2014 Jun 30. Bone Marrow Transplant. 2014. PMID: 24978140
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. Shimoni A, et al. Among authors: or r. Cancer. 2012 Oct 1;118(19):4706-14. doi: 10.1002/cncr.27418. Epub 2012 Jan 17. Cancer. 2012. PMID: 22252613 Free article. Clinical Trial.
Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).
Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, Mankuta D, Varda-Bloom N, Rheingold L, Yeshurun M, Bielorai B, Toren A, Zuckerman T, Nagler A, Or R. Resnick IB, et al. Among authors: or r. Am J Blood Res. 2013 Aug 19;3(3):225-38. eCollection 2013. Am J Blood Res. 2013. PMID: 23997985 Free PMC article.
446 results